Parvovirus infection and its treatment.
B19 parvovirus is an important pathogen in man. Acute infection produces fifth disease (erythema infectiosum) in normal individuals, transient aplastic crisis in the patient with haemolysis, and pure red cell aplasia in the immunologically incompetent host. Fetal infection can lead to hydrops fetalis. The target cell of the virus is the marrow erythroid progenitor. The immune response to the virus is largely humoral and directed against limited numbers of epitopes. Persistent infection is due to failure to produce neutralizing antibodies. Because viral infection is prevalent in the population, therapeutic immune globulin preparations are a good source of anti-B19 antibodies. IgG administration can lead to cure of anaemia in the congenitally immunodeficient patient and to its amelioration in AIDS patients with persistent parvovirus infection.
Young
N S
NS
Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, Maryland 20892, USA.
D000743:Anemia, Hemolytic / Q000628:therapy; D016731:Erythema Infectiosum / Q000628:therapy*; D015616:Histiocytosis, Non-Langerhans-Cell / Q000628:therapy; D006801:Humans; D015160:Hydrops Fetalis / Q000628:therapy; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D016732:Parvovirus B19, Human; D013577:Syndrome; D014765:Viral Vaccines / Q000627:therapeutic use
D016756:Immunoglobulins, Intravenous; D014765:Viral Vaccines